Overview of Keryx
Biopharmaceuticals, Inc.
Overview of Keryx
Biopharmaceuticals, Inc.
Based in New York City, Keryx Biopharmaceuticals,
Inc., develops and markets ph...
Overview of Keryx Biopharmaceuticals,
Inc.
Early supporters of Keryx
Biopharmaceuticals include biotechnology
investor Lin...
Upcoming SlideShare
Loading in …5
×

Overview of Keryx Biopharmaceuticals, Inc.

267 views

Published on

Based in New York City, Keryx Biopharmaceuticals, Inc., develops and markets pharmaceuticals for the treatment of patients with renal disease. In January 2013, the company completed phase three trials for the drug ferric citrate for the treatment of hyperphosphatemia (elevated phosphate levels in the blood) in patients living with chronic end-stage kidney disease. Marketed as Zerenex, ferric citrate is also in phase two trials for its use in stabilizing serum phosphorus levels and increasing iron stores in the blood of patients with both anemia and non-dialysis dependent chronic renal disease. Additionally, Keryx Biopharmaceuticals partners are currently seeking approval to market the drug in Japan.

Early supporters of Keryx Biopharmaceuticals include biotechnology investor Lindsay Rosenwald, MD, who heads Opus Point Partners as cofounder. Dr. Lindsay Rosenwald formerly served as a director and member of the company’s Board of Directors, stepping down in November 2008 to focus on other business undertakings. As of the present date, board members include Chairman Michael Tarnok, Jack Kaye, and Kevin Cameron.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
267
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Overview of Keryx Biopharmaceuticals, Inc.

  1. 1. Overview of Keryx Biopharmaceuticals, Inc.
  2. 2. Overview of Keryx Biopharmaceuticals, Inc. Based in New York City, Keryx Biopharmaceuticals, Inc., develops and markets pharmaceuticals for the treatment of patients with renal disease. In January 2013, the company completed phase three trials for the drug ferric citrate for the treatment of hyperphosphatemia (elevated phosphate levels in the blood) in patients living with chronic end-stage kidney disease. Marketed as Zerenex, ferric citrate is also in phase two trials for its use in stabilizing serum phosphorus levels and increasing iron stores in the blood of patients with both anemia and non-dialysis dependent chronic renal disease. Additionally, Keryx Biopharmaceuticals partners are currently seeking approval to market the drug in Japan.
  3. 3. Overview of Keryx Biopharmaceuticals, Inc. Early supporters of Keryx Biopharmaceuticals include biotechnology investor Lindsay Rosenwald, MD, who heads Opus Point Partners as cofounder. Dr. Lindsay Rosenwald formerly served as a director and member of the company’s Board of Directors, stepping down in November 2008 to focus on other business undertakings. As of the present date, board members include Chairman Michael Tarnok, Jack Kaye, and Kevin

×